Therapeutic benefits of the BET inhibitors have been observed in B-cell lymphoma [5] and acute myeloid leukemia [6, 7], as well as in lung [8], prostate [9], pancreatic [10], colorectal [11] and breast cancers [12]. This evidence concerns the gene DNER and breast carcinoma.